### **Anti-Hepatitis B Surface Antibodies (Anti-HBs) Test**
The **Anti-HBs (HBsAb) Titre test** is a quantitative blood assay that measures the concentration of protective antibodies against the Hepatitis B surface antigen.
* **Immunity Assessment:** It is primarily used to confirm immunity to the Hepatitis B virus (HBV), acquired either through successful vaccination or recovery from a past, resolved infection.
* **Clinical Threshold:** A titre level of **\ge 10 mIU/mL** is globally recognized as the threshold indicating active, long-term protective immunity against HBV.
* **Pre-employment & Monitoring:** This test is essential for healthcare workers, newborns of HBV-positive mothers, and immunocompromised patients to evaluate their defense status and determine the necessity of vaccine booster doses.

### **Anti-Chikungunya IgM Antibody Test**
The **Anti-Chikungunya IgM test** is a crucial serological assay for the early diagnosis of an active or recent infection with the Chikungunya virus. Immunoglobulin M (IgM) are the first antibodies produced by the immune system, typically appearing within 3 to 7 days after the onset of symptoms (primarily fever and severe joint pain).
A positive IgM result indicates a likely current or very recent infection, enabling rapid clinical intervention and public health response. The test is fundamental for differentiating Chikungunya from similar diseases like Dengue, as IgM antibodies typically remain detectable for several months before diminishing.

### **Anti-Chikungunya IgG Antibody Test**
The **Anti-Chikungunya IgG test** is a serological blood assay used to detect Immunoglobulin G (IgG) antibodies, which the immune system produces in response to the Chikungunya virus.
* **Clinical Significance:** IgG antibodies typically appear several weeks after the initial infection and can persist for months or even years, serving as a marker for past exposure or long-term immunity.
* **Diagnostic Utility:** It helps clinicians confirm previous infections, assess the prevalence of the virus in a population, and differentiate Chikungunya from other febrile illnesses like dengue or Zika.
* **Interpretation:** A positive result indicates that an individual was previously exposed to the virus, whereas a negative result suggests no past infection or that the test was performed too early.

### **Anti-Thyroid Peroxidase (Anti-TPO) Test**
The **Anti-TPO test** measures antibodies directed against thyroid peroxidase, an enzyme crucial for thyroid hormone synthesis.
* **Primary Diagnostic Tool:** It is the most sensitive laboratory marker for diagnosing autoimmune thyroid disorders, notably **Hashimoto’s thyroiditis** (the leading cause of hypothyroidism) and **Graves’ disease**.
* **Clinical Utility:** This test helps clinicians differentiate autoimmune thyroiditis from non-autoimmune goiters or general thyroid dysfunction.
* **Risk Assessment:** Identifying high anti-TPO levels is vital for evaluating the risk of postpartum thyroiditis and predicting the progression of subclinical hypothyroidism to overt thyroid disease, guiding timely treatment.

The Anti-Thyroglobulin Antibody (ATG) Test measures autoantibodies against thyroglobulin, a thyroid-produced protein. Elevated ATG levels indicate an autoimmune attack on the thyroid, often found in Hashimoto's thyroiditis and Graves' disease. The test is crucial for diagnosing autoimmune thyroiditis, distinguishing it from other thyroid conditions, and is especially significant in thyroid cancer cases. Elevated ATG in cancer follow-up can suggest recurrence or metastasis, affecting thyroglobulin (Tg) reliability as a tumor marker. Thus, ATG testing plays a key role in diagnosing autoimmune thyroid disease and monitoring thyroid cancer.

The **Anti-Thrombin III (ATIII) Antibody Test** is a specialized laboratory blood test used to investigate the specific cause of an anti-thrombin III deficiency. Anti-thrombin III is a natural anticoagulant protein that inhibits blood clotting. While functional ATIII assays measure the protein's activity, the antibody test specifically detects the presence of *acquired autoantibodies* that target and destroy ATIII.
This test is crucial for differentiating between an inherited deficiency (due to a genetic mutation) and an acquired deficiency caused by autoimmune disorders. The presence of these antibodies is strongly associated with an increased risk of severe, abnormal blood clots, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). Identification helps clinicians manage thrombotic risk and determine appropriate, targeted anticoagulant therapy.

### **Anti-Sperm Antibody (ASAB)**
**Anti-Sperm Antibodies (ASAB)** are immunoglobulins that mistakenly target sperm as foreign invaders. They can be present in both male and female reproductive tracts.
* **Impact on Fertility:** ASABs bind to sperm, causing them to clump together (agglutination), which severely hinders their motility and prevents them from swimming through the female cervical mucus.
* **Fertilization Barrier:** By coating the sperm head, these antibodies can block the crucial sperm-egg interaction, preventing successful fertilization.
* **Clinical Detection:** Commonly diagnosed using Semen Analysis (Mixed Antiglobulin Reaction / Immunobead tests) or blood ELISA assays, guiding decisions for assisted reproductive treatments like IVF or ICSI.

### **Anti-Scl-70 Antibody by ELISA**
The **Anti-Scl-70 (anti-topoisomerase I) antibody ELISA test** is a blood assay used to diagnose systemic sclerosis (scleroderma).
* **Diagnostic Target:** It detects autoantibodies directed against the intracellular enzyme topoisomerase I (Scl-70).
* **Clinical Significance:** A positive result is highly specific for **diffuse cutaneous systemic sclerosis**, a severe subtype characterized by widespread skin thickening and rapid progression.
* **Risk Assessment:** Presence of these antibodies is strongly associated with an increased risk of severe internal organ involvement, particularly **interstitial lung disease (ILD)** and cardiac complications.
* **Methodology:** The Enzyme-Linked Immunosorbent Assay (ELISA) provides a rapid, quantitative measure of antibody levels to guide early therapeutic intervention.

### **Anti-Phospholipid Antibody IgM**
**Anti-phospholipid IgM** is an autoantibody produced by the immune system that mistakenly targets the body's own cell membrane lipids and associated proteins.
* **Diagnostic Role:** It serves as a primary laboratory marker for diagnosing **Antiphospholipid Syndrome (APS)**, a systemic autoimmune disorder.
* **Associated Risks:** Elevated IgM levels are strongly linked to an increased risk of abnormal blood clots (thrombosis) and recurrent pregnancy complications.
* **Testing Protocol:** Clinicians typically test IgM alongside IgG antibodies. To confirm an APS diagnosis, a positive result must remain persistent when re-tested at least **12 weeks** apart to rule out transient elevations.

The Anti-Phospholipid Antibody (APLA) Test is a blood test used to detect antibodies that mistakenly attack the body's own phospholipids, increasing the risk of abnormal blood clotting. It helps diagnose Antiphospholipid Syndrome (APS), a condition associated with deep vein thrombosis, stroke, recurrent miscarriages, and certain autoimmune disorders such as lupus. Doctors may recommend this test for people with unexplained blood clots or repeated pregnancy loss. Early detection supports timely treatment, helping reduce complications and improve long-term health outcomes. The Anti-Phospholipid Antibody Test plays an important role in evaluating clotting disorders and guiding appropriate medical care.

The **Anti-Parietal Cell Antibody (APCA) test** is a crucial diagnostic tool used primarily to identify autoimmune gastritis and pernicious anemia. The test detects specialized autoantibodies in the blood that mistakenly target and destroy the stomach's parietal cells. These cells are responsible for producing both hydrochloric acid and Intrinsic Factor (IF). Because Intrinsic Factor is essential for Vitamin B12 absorption in the small intestine, its deficiency leads to B12 malabsorption. Over time, this causes the characteristic megaloblastic anemia and potential neurological damage. A positive APCA result, combined with low B12 levels, is highly indicative of autoimmune-mediated pernicious anemia.

The **Anti-Ovarian Antibody (AOA) test** is a blood test that detects autoantibodies targeting ovarian tissue, such as the granulosa cells, oocytes, or the corpus luteum. The presence of these antibodies indicates an autoimmune response where the body's immune system mistakenly attacks its own ovaries.

This test is primarily used as a diagnostic tool in investigating Premature Ovarian Insufficiency (POI)—also known as premature ovarian failure—and unexplained female infertility. By identifying an autoimmune etiology for decreased ovarian function, the AOA test helps clinicians distinguish autoimmune-mediated tissue damage from other causes of reproductive dysfunction.